Literature DB >> 25406371

[Prediction of overactive bladder treatment outcome by using long-term urodynamics].

S Wille1, D Tenholte, O A Cornely, N Muthen, U-H Engelmann, J Mehner, O Eminaga, J Herden, P Schumacher, J Paas.   

Abstract

In Germany, overactive bladder (OAB) syndrome affects around 6.5 million people over the age of 40. The primary treatment consists of anticholinergics or beta-3-receptor agonists. After an anticholinergic treatment period of around 4 months, compliance is around 40%, which is probably due a larger proportion of nonresponders. One condition of an efficient medication treatment is the presence of detrusor overactivity (DO). However, the detection rate of DO during standard urodynamics is very low. The primary goal in the future is to target OAB treatment by detection of DO. Using the Wille Capsule (WiCa) in an in vitro model, DO could be detected over a time period of 72 h, which would ensure a higher compliance to the OAB treatment in a positive way.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25406371     DOI: 10.1007/s00120-014-3629-7

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  15 in total

Review 1.  The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society.

Authors:  Paul Abrams; Linda Cardozo; Magnus Fall; Derek Griffiths; Peter Rosier; Ulf Ulmsten; Philip Van Kerrebroeck; Arne Victor; Alan Wein
Journal:  Urology       Date:  2003-01       Impact factor: 2.649

2.  [Is the validated ICIQ-SF suitable for evaluation of OAB patients? A data analysis of intravesicular botulinum toxin therapy].

Authors:  J Paas; N Muthen; V Weiß; S Wille
Journal:  Urologe A       Date:  2014-10       Impact factor: 0.639

3.  [EAU Guidelines on Urinary Incontinence].

Authors:  J W Thüroff; P Abrams; K-E Andersson; W Artibani; C R Chapple; M J Drake; C Hampel; A Neisius; A Schröder; A Tubaro
Journal:  Actas Urol Esp       Date:  2011-05-19       Impact factor: 0.994

4.  Is the bladder a reliable witness for predicting detrusor overactivity?

Authors:  H Hashim; P Abrams
Journal:  J Urol       Date:  2006-01       Impact factor: 7.450

5.  Validation of the urgency perception scale.

Authors:  Linda Cardozo; Karin S Coyne; Eboo Versi
Journal:  BJU Int       Date:  2005-03       Impact factor: 5.588

6.  The economic costs of overactive bladder in Germany.

Authors:  Theodor Klotz; Bernd Brüggenjürgen; Martin Burkart; Ansgar Resch
Journal:  Eur Urol       Date:  2006-11-27       Impact factor: 20.096

7.  Overactive bladder symptoms: do we need urodynamics?

Authors:  G Alessandro Digesu; Vik Khullar; Linda Cardozo; Stefano Salvatore
Journal:  Neurourol Urodyn       Date:  2003       Impact factor: 2.696

8.  Prevalence, severity, and symptom bother of lower urinary tract symptoms among men in the EPIC study: impact of overactive bladder.

Authors:  Debra E Irwin; Ian Milsom; Zoe Kopp; Paul Abrams; Walter Artibani; Sender Herschorn
Journal:  Eur Urol       Date:  2009-03-03       Impact factor: 20.096

9.  ICIQ: a brief and robust measure for evaluating the symptoms and impact of urinary incontinence.

Authors:  Kerry Avery; Jenny Donovan; Tim J Peters; Christine Shaw; Momokazu Gotoh; Paul Abrams
Journal:  Neurourol Urodyn       Date:  2004       Impact factor: 2.696

10.  EAU guidelines on assessment and nonsurgical management of urinary incontinence.

Authors:  Malcolm G Lucas; Ruud J L Bosch; Fiona C Burkhard; Francisco Cruz; Thomas B Madden; Arjun K Nambiar; Andreas Neisius; Dirk J M K de Ridder; Andrea Tubaro; William H Turner; Robert S Pickard
Journal:  Eur Urol       Date:  2012-08-31       Impact factor: 20.096

View more
  1 in total

1.  Tunable and Lightweight On-Chip Event Detection for Implantable Bladder Pressure Monitoring Devices.

Authors:  Robert Karam; Steve J A Majerus; Dennis J Bourbeau; Margot S Damaser; Swarup Bhunia
Journal:  IEEE Trans Biomed Circuits Syst       Date:  2017-10-11       Impact factor: 3.833

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.